Conference Coverage

Drs. James F. Donohue and Gary T. Ferguson address the following questions:

  • What are the changes regarding general assessment and management of COPD?
  • Should you ever think of using more than one long-acting bronchodilator as initial therapy (LAMA vs LABA/LAMA)?
  • What are the changes in the new recommendations regarding the use of ICS?

Play

CME/CE Information

Activity Title What’s the 2017 GOLD standard for managing patients with COPD?
Topic COPD
Accreditation Type AMA PRA Category 1 Credits
Release Date June 2, 2017
Expiration Date June 1, 2018
Estimated Time to Complete Activity 15 minutes

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

  • Examine data and expert recommendations concerning the use of ICS in patients with COPD
  • Evaluate data on the use of single and combination bronchodilators in patients with stable COPD
  • Discuss clinical scenarios in which, based on current evidence and/or recommendations, ICS should or should not be considered

ACTIVITY FACULTY

James F. Donohue, MD
University of North Carolina School of Medicine

Gary T. Ferguson, MD
Pulmonary Research Institute of Southeast Michigan

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  6. Your CME/CE certificate will be available for download.

CLICK HERE TO VIEW TECHNICAL REQUIREMENTS

ACCREDITED PROVIDER

This activity is provided by The France Foundation.

tff-logo250x43

TARGET AUDIENCE

These activities will target pulmonologists, critical care specialists, hospitalists, fellows and other health care providers who manage patients with COPD.

ACCREDITATION STATEMENT

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures

The following faculty report that they have relevant financial relationships to disclose:

  • James F. Donohue, MD, has served as a consultant for AstraZeneca, Circassia, Gilead Sciences, Inc., Novartis, and Sunovion Pharmaceuticals, Inc.
  • Gary T. Ferguson, MD, has served as a consultant for AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Innoviva, Meda Pharmaceuticals, Mylan, Novartis, Pearl Therapeutics, and Sunovion Pharmaceuticals, Inc. He has also received honoraria from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Meda Pharmaceuticals, and Sunovion Pharmaceuticals, Inc.

DISCLOSURE OF UNLABELED USE

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

DISCLAIMER

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION

Copyright © 2017 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or This email address is being protected from spambots. You need JavaScript enabled to view it..

 

 

Play

Access other Therapeutic Areas: